GlaxoSmithKline to buy Human Genome for $3bn

GSK headquarters The drugs industry has seen several takeovers and mergers recently

Related Stories

Drug company GlaxoSmithKline is to buy Human Genome Sciences for about $3bn (£1.9bn), ending a three-month pursuit of the US biotechnology firm.

The deal follows weekend talks in which the UK's largest pharmaceutical company agreed to raise its cash bid to $14.25 a share from $13.

The purchase gives GSK rights to several recently-launched medicines.

Major drugs companies are scouring the market for acquisitions as a wave of patents are about to expire.

GSK will gain control of Benlysta, which treats the immune system disorder lupus, as well as experimental medicines for diabetes and heart disease.

"Benlysta is actually going to be a good drug. Glaxo wanted to get this on the cheap and they were able to do it in the absence of other bidders," said analyst Carol Werter, from Summer Street Research.

Biotech companies are looking to acquire a new pipeline of drugs to replace older medicines that analysts say are expiring in record numbers.

Bristol-Myers Squibb recently bought diabetes specialist Amylin Pharmaceuticals by sharing the $7bn cost of the deal with AstraZeneca.

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Business stories

RSS

Features & Analysis

Elsewhere on the BBC

  • StuntmanStuntman to the stars

    Driving dangerously and falling off buildings are all part of the day job for Bobby Holland Hanton

Programmes

  • A digger operated via an Oculus Rift and a controllerClick Watch

    Why controlling a heavy digger with a virtual reality helmet might improve safety

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.